All entries for: Silexion Therapeutics Corp

March 17, 2026

Silexion Therapeutics Corp

Negative Outlook

Jerusalem, Israel
1-50 employees

We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes like the Inflation Reduction Act.

Disease Area: Oncology
Drug Type: Biologic
August 12, 2025

Silexion Therapeutics Corp

Neutral Outlook

Jerusalem, Israel
1-50 employees

President Biden signed the Inflation Reduction Act of 2022 (“IRA”) into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010.

Disease Area: Chronic Disease
Drug Type: Biologic, Small Molecule
May 28, 2025

Silexion Therapeutics Corp

Negative Outlook

Jerusalem, Israel
1-50 employees

Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved, and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes like the Inflation Reduction Act. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.

Disease Area: Oncology
Drug Type: Biologic
Scroll to Top